Lyxor MSCI Europe ESG Leaders (DR) UCITS ETF - Acc EUR is a equity ETF from Amundi tracking the MSCI Europe ESG Leaders index through physical replication. Domiciled in Luxembourg and launched in 2019, the fund manages about 1.1 bn € and charges a TER of 0.20% — 20 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
Lyxor MSCI Europe ESG Leaders (DR) UCITS ETF - Acc EUR competes with 261 other products in the same class and region (Equity, Europe): it ranks 36th by fund size and 83rd by ongoing cost, with a TER of 0.20% against a group median of 0.25%. It has been listed since 2019, 7 years of track record.
On a €10,000 investment the TER costs 20 € a year, against 25 € for the median product in the category.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 34.6% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in EUR. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Luxembourg, which determines the tax treatment of income received by the fund and the supervisory authority.
| ASML Holding N.V. | 6.5% |
| HSBC Holdings PLC | 4.6% |
| Novartis AG | 4.1% |
| AstraZeneca PLC | 4.0% |
| Nokia Oyj | 3.5% |
| Allianz SE VNA O.N. | 2.6% |
| Schneider Electric S.E. | 2.5% |
| ABB Ltd | 2.4% |
| Novo Nordisk A/S | 2.2% |
| Iberdrola S.A. | 2.2% |
| Borsa Italiana | ESGE | EUR |
| XETRA | LEAD | EUR |
| London Stock Exchange | ESGL | GBP |
| Euronext Paris | ESGE | EUR |
| SIX Swiss Exchange | ESGL | CHF |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.